A5065002546- Transplantation: Methods and Outcomes
- Renal Transplantation Outcomes and Treatments
- Mechanical Circulatory Support Devices
- Viral Infections and Immunology Research
- Cardiac Structural Anomalies and Repair
- Organ Transplantation Techniques and Outcomes
- Heart Failure Treatment and Management
- Organ and Tissue Transplantation Research
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
- Cytomegalovirus and herpesvirus research
- Cardiac Valve Diseases and Treatments
- Cardiovascular Issues in Pregnancy
- Polyomavirus and related diseases
- Cardiomyopathy and Myosin Studies
- Cardiac Arrest and Resuscitation
- Heparin-Induced Thrombocytopenia and Thrombosis
- Hepatitis C virus research
- Diabetes Treatment and Management
- Congenital Heart Disease Studies
- Liver Disease and Transplantation
- Eosinophilic Disorders and Syndromes
- Potassium and Related Disorders
Cedars-Sinai Medical Center
2016-2025
Cedars-Sinai Smidt Heart Institute
2016-2025
Joint Commission
2024
Saint Luke's Hospital
2024
Clinical Research Institute
2024
Bridgeport Hospital
2023
Sinai Hospital
2012-2023
Association of Chartered Certified Accountants
2020-2022
Cal Humanities
2022
American Heart Association
2021
The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in management patients with hypertrophic cardiomyopathy.
Importance Clinical guidelines for patients with heart failure reduced ejection fraction (HFrEF) strongly recommend treatment a sodium-glucose cotransporter-2 inhibitor (SGLT2i) to reduce cardiovascular mortality or HF hospitalization. Nationwide adoption of SGLT2i HFrEF in the US is unknown. Objective To characterize patterns use among eligible hospitalized HFrEF. Design, Setting, and Participants This retrospective cohort study analyzed 49 399 across 489 sites Get With The Guidelines–Heart...
Cardiomyopathy can be initiated by many factors, but the pathways from unique inciting mechanisms to common end point of ventricular dilation and reduced cardiac output are unclear. We previously described a microarray-based prediction algorithm differentiating nonischemic (NICM) ischemic cardiomyopathy (ICM) using nearest shrunken centroids. Accordingly, we tested hypothesis that NICM ICM would have both shared distinct differentially expressed genes relative normal hearts compared gene...
Disruption of leptin signaling is associated with obesity, heart failure, and cardiac hypertrophy, but the role in myocyte apoptosis unknown. We tested hypothesis that increases leptin-deficient ob/ob leptin-resistant db/db mice aging left ventricular increased DNA damage, decreased survival. studied young (2- to 3-month-old) old (12- 14-month-old) wild-type (WT) controls (n=2 4 per group). As expected, wall thickness weights were similar among , WT mice, higher versus WT. Young showed...